Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Liabilities (2016 - 2025)

Guided Therapeutics' Total Liabilities history spans 16 years, with the latest figure at $7.3 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 16.96% to $7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 16.96% increase, with the full-year FY2025 number at $7.3 million, up 16.96% from a year prior.
  • Total Liabilities hit $7.3 million in Q4 2025 for Guided Therapeutics, up from $6.5 million in the prior quarter.
  • Over the last five years, Total Liabilities for GTHP hit a ceiling of $10.3 million in Q1 2021 and a floor of $5.5 million in Q4 2023.
  • Historically, Total Liabilities has averaged $6.6 million across 5 years, with a median of $6.3 million in 2024.
  • Biggest five-year swings in Total Liabilities: crashed 57.44% in 2021 and later rose 16.96% in 2025.
  • Tracing GTHP's Total Liabilities over 5 years: stood at $7.5 million in 2021, then dropped by 16.51% to $6.2 million in 2022, then fell by 12.39% to $5.5 million in 2023, then increased by 14.47% to $6.3 million in 2024, then rose by 16.96% to $7.3 million in 2025.
  • Business Quant data shows Total Liabilities for GTHP at $7.3 million in Q4 2025, $6.5 million in Q3 2025, and $6.4 million in Q2 2025.